Menu
No results found.
Weekly Share Price & Valuation Overview
Herantis Pharma Oyj
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. The company was incorporated in 2008 and is based in Espoo, Finland.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- EUR 46.14M
- Enterprise Value Operating value: market cap + total debt − cash.
- EUR 35.34M
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -0.24
- Shares Outstanding
- 24.09M
- Float Shares
- 14.83M
- Implied Shares Outstanding
- 24.09M
- ROA Return on assets: net income ÷ total assets.
-
-67.44%
- ROE Return on equity: net income ÷ shareholder equity.
-
-2.20%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
30.00%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 4.01
- Total Cash Cash and equivalents.
- EUR 2.13M
- Total Debt Short + long-term interest-bearing debt.
- EUR 73.97K
- Net Debt Net Cash Total debt − cash (negative = net cash).
- EUR -2.06M
- Revenue per Share (TTM) computed from resolved revenue ÷ shares due to feed inconsistency.
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.